Neurogene Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
Consolidated Statements of Cash Flows
(In Thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(75,144) | $(36,317) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 8,320 | 1,418 |
| Bargain purchase gain in connection with reverse merger | — | (16,355) |
| Depreciation and amortization of property and equipment | 3,195 | 3,262 |
| Asset impairment | 91 | — |
| Non-cash operating lease expense | 741 | 663 |
| Amortization of finance lease right-of-use assets | 52 | 35 |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | (2,419) | (105) |
| Contingent value rights liability | 522 | — |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (327) | 326 |
| Other assets | (211) | (764) |
| Accounts payable | (77) | 667 |
| Accrued expenses and other liabilities | (2,773) | (3,574) |
| Operating lease liabilities | (2,573) | (678) |
| Net cash used in operating activities | (70,603) | (51,422) |
| Investing activities | ||
| Purchases of property and equipment | (808) | (321) |
| Cash and restricted cash acquired from reverse merger transaction | — | 22,243 |
| Reverse merger transaction costs paid | — | (1,285) |
| Purchases of held-to-maturity investments | (198,453) | — |
| Proceeds from maturities of held-to-maturity investments | 74,000 | 5,000 |
| Net cash (used in) provided by investing activities | (125,261) | 25,637 |
| Financing activities | ||
| Proceeds from pre-closing financing, net of offering costs paid | — | 92,343 |
| Offering costs in connection with pre-closing financing | (4,287) | — |
| Transaction costs related to reverse merger | (2,855) | — |
| Proceeds from the issuance of common stock upon exercise of options | 1,676 | 168 |
| Proceeds from private financing, net of offering costs paid | 189,589 | — |
| Principal payments on finance leases | (52) | (29) |
| Net cash provided by financing activities | 184,071 | 92,482 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (11,793) | 66,697 |
| Cash, cash equivalents and restricted cash at beginning of period | 148,718 | 82,021 |
| Cash, cash equivalents and restricted cash at end of period | $136,925 | $148,718 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Additions to operating lease right of use assets from new operating lease liabilities | $60 | $— |
| Property and equipment included in accounts payable and accrued expenses | $726 | $— |
| Additions to finance lease right of use assets from new finance lease liabilities | $25 | $46 |
| Offering costs related to private offering, included in accounts payable and accrued expenses | $90 | $— |
| Operating lease liabilities assumed in connection with the reverse merger | $— | $10,940 |
| Contingent consideration liability assumed in the reverse merger | $— | $1,287 |
| Other liabilities assumed in the reverse merger | $— | $10,110 |
| Assets acquired in the reverse merger including $53.9 million in ST investments and $0.8 million in other monetary assets | $— | $54,661 |
| Issuance of common stock and pre-funded warrants to former stockholders of Neoleukin Therapeutics, Inc. in connection with the reverse merger | $— | $38,212 |
| Offering costs in connection with pre-closing financing included in accounts payable and accrued expenses | $— | $4,287 |
| Transaction costs related to reverse merger included in accounts payable and accrued expenses | $— | $2,855 |
| Conversion of preferred stock into common stock in connection with reverse merger | $— | $244,366 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $12 | $12 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.